<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81615">
  <stage>Registered</stage>
  <submitdate>23/09/2006</submitdate>
  <approvaldate>27/09/2006</approvaldate>
  <actrnumber>ACTRN12606000418572</actrnumber>
  <trial_identification>
    <studytitle>The effect of continuous positive airway pressure in heart failure and obstructive sleep apnoea on left ventricular function</studytitle>
    <scientifictitle>The effect of continuous positive airway pressure in heart failure and obstructive sleep apnoea on left ventricular function</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Heart failure / obstructive sleep apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Non randomised parallel study.                                                                                                                                                                                                                                      Intervention group: Continuous positive airway pressure (CPAP) device used for treating obstructive sleep apnoea to be used each sleeping period at home.  This is a standard treatment device for treating obstructive sleep apnoea.  It involves sleeping with a nasal or full face mask attached to the pressure machine.  The pressure is individually determined for each subject via titration.  Duration for both groups 6 months.</interventions>
    <comparator>Control Group: usual medical treatment  ie continued medication for heart failure as per primary care physician instructions.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Left Ventricular Ejection Fraction </outcome>
      <timepoint>Measured at 6 months followup after baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Daytime sleepiness</outcome>
      <timepoint>Measured at baseline and at 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Measured at baseline and at 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults with heart failure (Left ventricular ejection fraction &lt; 45%) and Obstructive Sleep Apnoea (Apnoea/hypopnoea index &gt; 10/hr).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Renal failure, respiratory failure, pyschiatric history, alcohol dependancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>26</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Otago University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Wellington Medical Research Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Research Administrator, Christine Groves, Wellington School of Medicine</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed to provide evidence of whether patients with heart failure and obstructive sleep apnoea gain benefit from Continuous Positive Airway Pressure treatment not only in terms of treating Obstructive Sleep Apnoea  but on heart function as well.  The study hypothesis is that CPAP will have a beneficial effect on heart function as measured by an increase in left ventricular ejection fraction.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>WellSleep-Wellington Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/09/2000</ethicapprovaldate>
      <hrec>00/09/107</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Alister Neill</name>
      <address>Wellington School of Medicine
Po Box 7343
Wellington South</address>
      <phone>+64 4 3855999</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Alister Neill</name>
      <address>Wellington School of Medicine
Po Box 7343
Wellington</address>
      <phone>+64 4 3855999</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>